260 related articles for article (PubMed ID: 34290359)
1. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.
Bae J; Accardi F; Hideshima T; Tai YT; Prabhala R; Shambley A; Wen K; Rowell S; Richardson PG; Munshi NC; Anderson KC
Leukemia; 2022 Jan; 36(1):138-154. PubMed ID: 34290359
[TBL] [Abstract][Full Text] [Related]
2. Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.
Ninkovic S; Purton LE; Harrison SJ; Quach H
Haematologica; 2024 May; 109(5):1487-1500. PubMed ID: 37855027
[TBL] [Abstract][Full Text] [Related]
3. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.
Bae J; Prabhala R; Voskertchian A; Brown A; Maguire C; Richardson P; Dranoff G; Anderson KC; Munshi NC
Leukemia; 2015 Jan; 29(1):218-29. PubMed ID: 24935722
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.
Bae J; Hideshima T; Zhang GL; Zhou J; Keskin DB; Munshi NC; Anderson KC
Leukemia; 2018 Mar; 32(3):752-764. PubMed ID: 29089645
[TBL] [Abstract][Full Text] [Related]
5. PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Mussetti A; Pellegrinelli A; Cieri N; Garzone G; Dominoni F; Cabras A; Montefusco V
Ann Hematol; 2019 Jul; 98(7):1713-1720. PubMed ID: 31053880
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8
Bae J; Samur M; Richardson P; Munshi NC; Anderson KC
Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779
[TBL] [Abstract][Full Text] [Related]
7. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
8. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
Bae J; Tai YT; Anderson KC; Munshi NC
Br J Haematol; 2011 Nov; 155(3):349-61. PubMed ID: 21902685
[TBL] [Abstract][Full Text] [Related]
9. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
10. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.
Rosenblatt J; Glotzbecker B; Mills H; Vasir B; Tzachanis D; Levine JD; Joyce RM; Wellenstein K; Keefe W; Schickler M; Rotem-Yehudar R; Kufe D; Avigan D
J Immunother; 2011 Jun; 34(5):409-18. PubMed ID: 21577144
[TBL] [Abstract][Full Text] [Related]
12. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.
Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE
Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183
[TBL] [Abstract][Full Text] [Related]
13. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
14. Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro.
Frassanito MA; Ruggieri S; Desantis V; Di Marzo L; Leone P; Racanelli V; Fumarulo R; Dammacco F; Vacca A
Eur J Haematol; 2015 Jul; 95(1):65-74. PubMed ID: 25409753
[TBL] [Abstract][Full Text] [Related]
15. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
Bae J; Smith R; Daley J; Mimura N; Tai YT; Anderson KC; Munshi NC
Clin Cancer Res; 2012 Sep; 18(17):4850-60. PubMed ID: 22753586
[TBL] [Abstract][Full Text] [Related]
16. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden.
Halapi E; Werner A; Wahlström J; Osterborg A; Jeddi-Tehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
Eur J Immunol; 1997 Sep; 27(9):2245-52. PubMed ID: 9341766
[TBL] [Abstract][Full Text] [Related]
17. Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
Miguel-Garcia A; Matutes E; Tarin F; Garcia-Talavera J; Miguel-Sosa A; Carbonell F; Catovsky D
J Clin Pathol; 1995 Sep; 48(9):835-9. PubMed ID: 7490317
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
Korde N; Kristinsson SY; Landgren O
Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the role of Tregs in the progression of multiple myeloma.
Lad D; Huang Q; Hoeppli R; Garcia R; Xu L; Levings M; Song K; Broady R
Leuk Lymphoma; 2019 Sep; 60(9):2134-2142. PubMed ID: 30773086
[TBL] [Abstract][Full Text] [Related]
20. Treg and Oligoclonal Expansion of Terminal Effector CD8
Joshua DE; Vuckovic S; Favaloro J; Lau KHA; Yang S; Bryant CE; Gibson J; Ho PJ
Front Immunol; 2021; 12():620596. PubMed ID: 33708212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
